Predicting the future: A critical appraisal of cancer prognosis studies

Histopathology

Volumn 35, Issue 6, 1999, Pages 489-494

  Hall, P A ^b   Going, J J ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b NONE

Author keywords

Cancer; Methodology; Neoplasia; Prognosis

Indexed keywords

CANCER MORTALITY; CANCER RESEARCH; CLINICAL PRACTICE; HISTOPATHOLOGY; HUMAN; METHODOLOGY; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

FORECASTING; HUMANS; NEOPLASMS; PROGNOSIS; TREATMENT OUTCOME;

EID: 0033407503     PISSN: 03090167     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2559.1999.00862.x     Document Type: Review

References (33)

1. 1. Gospodarowicz MK, Hermanek P, Henson DE. Introduction. In: Hermanek P, Gospodarowicz MK, Henson DE, Hutter RVP, Sobin LH, eds. Prognostic Factors in Cancer. Berlin, Springer Verlag, 1993: 1-11.
2. 2. Katzenstein HM, Bowman LC, Brodeur GM et al. Prognostic significance of age, MYCN oncogene amplification, tumour cell ploidy, and histology in 110 infants with stage D (S) neuroblastoma: the Pediatric Oncology Group experience. J. Clin. Oncol. 1998; 16; 2007-2017.
3. 3. Sauerbrei W, Hubner K, Schoor C, Schumacher M. Validation of existing and development of new prognostic classification schemes in node negative breast cancer. Breast Cancer Res. Treat. 1997; 42; 149-163.
4. 4. Sundquist M, Thorstenson S, Brudin L, Nordenskjold B. Applying the Nottingham prognostic index to a swedish breast cancer population. Breast Cancer Res. Treat. 1999; 53; 1-8.
5. 5. Altman DG. Practical Statistics for Medical Research. London: Chapman & Hall, 1991.
6. 6. Wilman KG. New p53-based anti-cancer therapeutic strategies. Med. Oncol. 1998; 15; 222-228.
7. 7. Kohl NE, Omer CA, Conner MW et al. Inhibition of farnesyl-transferase induces regression of mammary and salivary tumours in ras transgenic mice. Nature Med. 1995; 1; 792-797.
8. 8. Glass L, Mackay MC. From clocks to chaos: the rhythms of life. Princeton, New Jersey: Princeton University Press, 1988.
9. 9. Kauffman S. At Home in the Universe: the Search for Laws of Complexity. New York: Oxford University Press, 1995.
10. 10. Bloom HJG, Richardson WW. Histological grading and prognosis in breast cancer. Br. J. Cancer 1957; 11; 359-377.
11. 11. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 19; 403-410.
12. 12. Altman DG, Lausen B, Sauerbrei W, Schumacher M. Dangers of using 'optimal' cutpoints in the evaluation of prognostic factors. J. Natl. Cancer Inst. 1994; 86; 829-835.
13. 13. Altman DG, Lyman GH. Methodological challenges in the evaluation of prognostic factors in breast cancer. Breast Cancer Res. Treat. 1998; 52; 289-303.
14. 14. Simon R, Altman DG. Statistical aspects of prognostic factor studies in oncology. Br. J. Cancer 1994; 69; 979-985.
15. 15. Hall PA, Lane DP. p53 in tumour pathology: Can we trust immunohistochemistry - revisited. J. Pathol. 1994; 172; 1-4.
16. 16. Jain S, Filipe NI, Hall PA, Waseem NH, Lane DP, Levison DA. The prognostic significance of proliferating cell nuclear antigen (PCNA) immunostaining in gastric cancer. J. Clin. Pathol. 1991; 44; 655-659.
17. 17. Gundersen HJG, Bendtsen TF, Korbo L et al. Some new, simple and efficient stereological methods and their use in pathological research and diagnosis. Acta Patholog. Microbiolog. Scand. 1988; 96; 379-394.
18. 18. Gundersen HJG, Bagger P, Bendtsen TF et al. The new stereological tools: Disector, fractionator, nucleator and point sampled intercepts and their use in pathological research and diagnosis. Acta Patholog. Microbiolog. Scand. 1988; 96; 857-881.
19. 19. Howard CV, Reed MG. Unbiased stereology. Three-Dimensional Measurement in Microscopy. Oxford: Bios Scientific Publishers and the Royal Microscopical Society, 1998.
20. 20. Simpson JF, Page DL. Cellular proliferation and prognosis in breast cancer: statistical purity versus clinical utility. Hum. Pathol. 1994; 25; 331-332.
21. 21. Going J. Efficiently estimated histologic cell counts. Hum. Pathol. 1994; 25; 333-336.
22. 22. Baak JPA, Van Diest PJ. The multicenter morphometric mammary carcinoma project. A nationwide prospective study on reproducibility and prognostic power of routine quantitative assessments in the Netherlands. Pathol. Res. Practice 1989; 185; 664-670.
23. 23. Beliën JAM, Somi S, Jong J, Sd Van Diest PJ, Baak JPA. Fully automated microvessel counting and hot spot selection by image processing of whole tumour sections in invasive breast cancer. J. Clin. Pathol. 1999; 52; 184-192.
24. 24. Van Diest PJ, Brugel G, Baak JPA. Proliferation markers in tumours: interpretation and clinical value. J. Clin. Pathol. 1998; 51; 716-724.
25. 25. Beliën JAM, Baak JPA, Van Diest JP et al. Counting mitoses by image processing in Feulgen stained breast cancer sections. the influence of resolution. Cytometry 1997; 28; 135-140.
26. 26. Vinci AD, Geido E, Pfeffer U et al. Quantitative analysis of mitotic and early-G1 cells using monoclonal antibodies against the AF-2 protein. Cytometry 1993; 14; 421-427.
27. 27. Sokhal RR, Rohlf FJ. Estimation and hypothesis testing. Biometry: the Principles and Practice of Statistics in Biological Research. New York: WH Freeman, 1981; 128-178.
28. 28. Altman DG. How Large a Sample? Statistics in Practice. London: British Medical Association, 1982, 6-8.
29. 29. Barrett PL, Seymour MT, Stenning S, Birbeck KF, Quirke P, AXIS collaborators, Molecular markers and the prediction of prognosis and response to therapy in colon cancer. Summer Meeting, Pathological Society of Great Britain and Ireland, Dundee, Scotland, 1999.
30. 30. Hall PA, Richards MA, Gregory WM, d'Ardenne AJ, Lister TA, Stansfeld AG. The prognostic value of Ki67 immunostaining in non-Hodgkin's lymphoma. J. Pathol. 1988; 154; 223-235.
31. 31. O'Reilly SM, Camplejohn RS, Barnes DM et al. DNA index, S-phase fraction, histological grade and prognosis in breast cancer. Br. J. Cancer 1990; 61; 671-674.
32. 32. O'Reilly SM, Camplejohn RS, Barnes DM, Millis RR, Rubens RD, Richards MA. Node negative breast cancer: prognostic subgroups defined by tumour size and flow cytometry. J. Clin. Oncol. 1990; 8; 2040-2046.
33. 33. Dowell SP, Hall PA. The p53 tumour-suppressor gene and tumour prognosis-is there a relationship? J. Pathol. 1995; 177; 221-224.